Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp146 | Paediatric Endocrinology & Development | ECE2016

Breast development in male-to-female transgender patients after one year cross-sex hormonal treatment

de Blok Christel , Klaver Maartje , Nota Nienke , Dekker Marieke , den Heijer Martin

Background: In male to female transgender patients breast development is a key part in the process of feminization using cross sex hormone therapy. In the Endocrine Society’s clinical guideline ‘Endocrine treatment of transsexual persons’ the onset of breast growth is estimated as 3–6 months after starting cross sex hormone treatment. The maximum breast growth however is seen after 2–3 years. But how much growth, in centimeters or cup-sizes, we can exp...

ea0041ep397 | Developmental endocrinology | ECE2016

Cross-sex hormone therapy affects body fat distribution in transgender persons

Klaver Maartje , Dekker Marieke , Schreiner Thomas , Fisher Alessandra , T'sjoen Guy , den Heijer Martin

Introduction: Fat distribution is an important secondary sex characteristic, which is generally peripherally or pear-shaped (gynoid) in females and centrally or apple-shaped (android) in males. Total body fat increases in male-to-females (MtFs) and decreases in female-to-males (FtMs) during cross-sex hormone therapy (CSHT), approaching body fat amounts of the desired sex. However, changes in android or gynoid fat distribution might be a better measure for masculinization and f...

ea0041ep961 | Steroid metabolism + action | ECE2016

Increase in insuline-like growh factor levels during cross-sex hormone treatment in transgender persons

Nota Nienke , Dekker Marieke , Klaver Maartje , Wiepjes Chantal , Heijboer Annemieke , den Heijer Martin

Background: Sex steroids probably stimulate growth-hormone secretion during puberty, which in turn contributes to the development of gender specific body characteristics. Hypothetically, adequate growth hormone levels in transgender persons are also important to achieve the best therapeutic results. The influence of cross-sex hormone treatment (CHT) at growth-hormone production in adult transgender persons is not yet elucidated.Objective: To investigate ...

ea0037gp.10.05 | Calcium, Vitamin D and Bone | ECE2015

Effect of 1-year cross-sex hormonal treatment on bone mineral density of the lumbar spine in transgender patients

Vlot Mariska , Klaver Maartje , Lips Paul , de Jongh Renate , Heijboer Annemieke , den Heijer Martin

Background: Oestrogen can increase bone mineral density (BMD) by decreasing bone turnover, which is mainly seen in trabecular bone. Testosterone can increase bone size, but the effect on BMD is less clear. Cross-sex hormonal treatment (CSHT) in transsexuals can therefore affect the BMD. For example, in male-to-female individuals (MtFs) a lower BMD before start of CSHT has been described in comparison to healthy control men.Objectives: To investigate the ...

ea0037gp.13.05 | Diabetes and obesity – Translational cardiovascular and obesity | ECE2015

The effects of cross-sex hormone therapy on body weight and fat percentage in transgender individuals

Klaver Maartje , Vlot Mariska , Dekker Marieke , Megens Jos , Heijer Martin den

Introduction: Cross-sex hormone therapy is part of the treatment of individuals with gender dysphoria and affects several factors such as body composition and thereby cardiovascular risk. However, little is known about the specific effects on body weight and fat percentage in the first year of treatment.Aim: The aim of this study is to examine the effects of cross-sex hormones on body weight and total fat percentage during the first year of treatment.</p...

ea0037ep130 | Steroids, development and paediatric endocrinology | ECE2015

Serum prolactin levels in transgender persons before and during cross-sex hormonal treatment

Nota Nienke , Klaver Maartje , den Heijer Martin , Dekker Marieke , Heijboer Annemieke

Introduction: Gender dysphoria refers to the incongruence between the subject’s experienced sex on the one hand and the assigned sex on the other hand. Several studies assume a relationship between oestrogen substitution therapy and serum prolactin levels.Aim: The aim of this study is to get more insight into the effect and time-course of changes in serum prolactin levels during cross-sex hormone therapy.Methods: This prospect...

ea0056p982 | Steroid metabolism + action | ECE2018

Polycythemia in transmen – Prevalence, determinants and outcome in a large cohort

Dijk Dennis van , Wiepjes Chantal , Blok Christel de , Klaver Maartje , Nota Nienke , Tebbens Marieke , Heijer Martin den , Conemans Elfi

Introduction: Testosterone is known to have an effect on hematocrit levels, with polycythemia as an unwanted side effect. An increase in hematocrit levels is also seen in transmen after starting cross-sex hormonal treatment (CHT) with testosterone. The aim of this study is to investigate the effect of cross-sex hormonal treatment with testosterone on hematocrit levels in the context of the safety aspects of this treatment. The prevalence, determinants and outcome of secondary ...

ea0041oc11.1 | Bone &amp; Calcium Homeostasis | ECE2016

An increase of bone mineral density in male-to-female and female-to-male transgender persons after one year cross-sex hormonal treatment

Wiepjes Chantal , Vlot Mariska , Klaver Maartje , de Jongh Renate , Lips Paul , Heijboer Annemieke , Fisher Alessandra , Schreiner Thomas , T'Sjoen Guy , den Heijer Martin

Introduction: Estrogen has positive effects on bone mineral density (BMD), in particular in trabecular bone through inhibition of bone resorption. Testosterone increases bone size, but the effect on BMD is less clear. Cross-sex hormonal treatment (CSHT) in transgender individuals can affect BMD. Therefore, the aim of this study is to investigate effects of CSHT on BMD during the first year of treatment in male-to-female (MtFs) and female-to-male (FtMs) transgender persons....

ea0056gp222 | Reproduction | ECE2018

Change in visceral fat and its relation with change in lipids in trans persons during hormonal therapy: results from a multicenter prospective study

Klaver Maartje , Wiepjes Chantal , de Blok Christel , Nota Nienke , Defreyne Justine , Schneider Thomas , Fisher Alessandra , T'Sjoen Guy , den Heijer Martin , de Mutsert Renee

Introduction: Excess visceral adipose tissue (VAT) is strongly related to multiple cardiovascular risk factors such as dyslipidemia. Hormonal therapy (HT) in trans persons affects total body fat and body fat distribution, but the effect on VAT and its relation to changes in lipids is unknown. The aim of our study was to investigate the effect of one year HT on changes in VAT and its relation with changes in total cholesterol, HDL, LDL, and triglycerides after one year of HT.</...